Evidence map›Paper›PMID 36142301›Full record

ReviewInternational journal of molecular sciences2022

Therapeutic Potential and Mechanisms of Novel Simple O-Substituted Isoflavones against Cerebral Ischemia Reperfusion.

Shu-Er Yang, Jin-Cherng Lien, Chia-Wen Tsai, Chi-Rei Wu

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Isoflavone-EnrichedInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. [Geniposide inhibits retinal cell apoptosis induced by glaucoma through the Hspa1a pathway].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  7. Formononetin: pharmacological properties and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Systematic Engineering ofJournal of fungi (Basel, Switzerland) · 2024
    Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shu-Er YangDepartment of Beauty Science and Graduate Institute of Beauty Science Technology, Chienkuo Technology University, Changhua City 500020, Taiwan.ORCID 0000-0001-9593-484X
Jin-Cherng LienSchool of Pharmacy, China Medical University, Taichung 404328, Taiwan.ORCID 0000-0002-1211-0245
Chia-Wen TsaiDepartment of Nutrition, China Medical University, Taichung 404328, Taiwan.
Chi-Rei WuDepartment of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 404328, Taiwan.ORCID 0000-0002-7036-5035
China Medical University · TWChienkuo Technology University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isoflavones have been widely studied and have attracted extensive attention in fields ranging from chemotaxonomy and plant physiology to human nutrition and medicine. Isoflavones are often divided into three subgroups: simple O-substituted derivatives, prenylated derivatives, and glycosides. Simple O-substituted isoflavones and their glycosides, such as daidzein (daidzin), genistein (genistin), glycitein (glycitin), biochanin A (astroside), and formononetin (ononin), are the most common ingredients in legumes and are considered as phytoestrogens for daily dietary hormone replacement therapy due to their structural similarity to 17-β-estradiol. On the basis of the known estrogen-like potency, these above isoflavones possess multiple pharmacological activities such as antioxidant, anti-inflammatory, anticancer, anti-angiogenetic, hepatoprotective, antidiabetic, antilipidemic, anti-osteoporotic, and neuroprotective activities. However, there are very few review studies on the protective effects of these novel isoflavones and their related compounds in cerebral ischemia reperfusion. This review primarily focuses on the biosynthesis, metabolism, and neuroprotective mechanism of these aforementioned novel isoflavones in cerebral ischemia reperfusion. From these published works in in vitro and in vivo studies, simple O-substituted isoflavones could serve as promising therapeutic compounds for the prevention and treatment of cerebral ischemia reperfusion via their estrogenic receptor properties and neuron-modulatory, antioxidant, anti-inflammatory, and anti-apoptotic effects. The detailed mechanism of the protective effects of simple O-substituted isoflavones against cerebral ischemia reperfusion might be related to the PI3K/AKT/ERK/mTOR or GSK-3β pathway, eNOS/Keap1/Nrf-2/HO-1 pathway, TLRs/TIRAP/MyD88/NFκ-B pathway, and Bcl-2-regulated anti-apoptotic pathway. However, clinical trials are needed to verify their potential on cerebral ischemia reperfusion because past studies were conducted with rodents and prophylactic administration.

Indexed as

Brain IschemiaIsoflavonesAnti-Inflammatory AgentsAntioxidantsEstradiolEstrogensGenisteinGlycogen Synthase Kinase 3 betaHumansHypoglycemic AgentsKelch-Like ECH-Associated Protein 1Myeloid Differentiation Factor 88NF-E2-Related Factor 2Phosphatidylinositol 3-KinasesPhytoestrogensProto-Oncogene Proteins c-aktAnti-Inflammatory AgentsAntioxidantsEstradiolEstrogensGenisteinGlycogen Synthase Kinase 3 betaHypoglycemic AgentsIsoflavonesKelch-Like ECH-Associated Protein 1Myeloid Differentiation Factor 88NF-E2-Related Factor 2Phosphatidylinositol 3-KinasesPhytoestrogensProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2TOR Serine-Threonine Kinasesbiosynthesiscerebral ischemia reperfusionisoflavonesmetabolism

Identifiers

PMID36142301
PMCPMC9498989
OpenAlexW4295207014

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.